Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549753 | 1.00 | KDM4E (0.51) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL2700904 | 1.00 | KDM4E (0.51) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL550050 | 1.00 | KDM4E (0.51) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL549754 | 1.00 | KDM4E (0.51) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL550051 | 1.00 | KDM4E (0.51) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL550028 | 0.90 | KDM4E (0.44) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL2699645 | 0.90 | KDM4E (0.44) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL550372 | 0.90 | KDM4E (0.44) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL2699639 | 0.90 | KDM4E (0.44) | KDM4ERECQLMAPTALDH1A1NPSR1 | |
| SCHEMBL550027 | 0.90 | KDM4E (0.44) | KDM4ERECQLMAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | KDM4E 3021/4885RECQL 3329/4885MAPT 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.